The Filing Desk

Amylyx Pharmaceuticals

AMLX · Nasdaq · Health Care · Financials, fiscal 2021 to 2025

AMLX · Last close · November 13, 2026
$30.29
Value Amylyx Pharmaceuticals yourself

Amylyx Pharmaceuticals' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$123 million. The diluted share count rose 38.8%.

Amylyx Pharmaceuticals, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001193125-26-086645 Updated
Revenue
$0M
100.0%
Net margin
—
 
Net income
−$145M
 
Free cash flow
−$123M
 
Return on equity
−61.6%
39.3 pts
Market cap
$3.6B
Nov 13 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Gross margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Operating margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Net margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Amylyx Pharmaceuticals does

Amylyx Pharmaceuticals is a clinical-stage drug company, which means it has no approved product on the market and is still testing its medicines in people. Its programs target endocrine conditions and neurodegenerative diseases.

Its lead candidate is avexitide, which blocks the receptor for a hormone called GLP-1. It is being studied for post-bariatric hypoglycemia (dangerously low blood sugar after weight-loss surgery) and for congenital hyperinsulinism, a condition in which the body makes too much insulin. The company says there are no approved therapies for the first condition. The U.S. Food and Drug Administration has given avexitide special designations for these uses, and a Phase 3 trial in post-bariatric hypoglycemia is under way at sites in the U.S.

Amylyx stopped selling its earlier product in the U.S. and Canada, so it no longer earns revenue from it. It expects to need substantial new funding to pursue its plans.

Its biggest risks, as it describes them

  • It depends heavily on the success of avexitide and its other main candidate, AMX0035.
  • It has stopped selling its earlier product and will not return to profit unless a new product succeeds.
  • It expects to need substantial new funding, and raising it may dilute shareholders.
  • Its reliance on third parties to run trials and make its medicines.
From Amylyx Pharmaceuticals's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Amylyx Pharmaceuticals lost money in fiscal 2025: a net loss of $145 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments96347371176317
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio6.0x8.2x5.7x6.7x14.3x
Quick ratio6.0x8.0x5.2x6.7x14.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Amylyx Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $152,183 of Amylyx Pharmaceuticals shares on the open market, and 5 insiders sold $16.4 million, $7.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 10, 2026James M FratesChief Financial OfficerSold plan20,000$30.55$611,090Form 4
Nov 9, 2026Justin B. KleeCo-Chief Executive Officer, DirectorSold plan100,000$29.84$3.0 millionForm 4
Nov 9, 2026Joshua B CohenCo-Chief Executive Officer, DirectorSold plan100,000$29.84$3.0 millionForm 4
Nov 9, 2026James M FratesChief Financial OfficerSold plan20,000$29.83$596,652Form 4
Sep 10, 2026Joshua B CohenCo-Chief Executive Officer, DirectorSold30,464$32.19$980,632Form 4
Sep 10, 2026Justin B. KleeCo-Chief Executive Officer, DirectorSold30,464$32.18$980,290Form 4
Sep 10, 2026James M FratesChief Financial OfficerSold10,810$32.36$349,839Form 4
Sep 10, 2026Camille L BedrosianChief Medical OfficerSold10,028$32.39$324,833Form 4
Sep 10, 2026Gina MazzarielloChief Legal OfficerSold9,536$32.46$309,548Form 4
Jul 10, 2026Gina MazzarielloChief Legal OfficerSold plan15,000$17.61$264,150Form 4
Jul 9, 2026Gina MazzarielloChief Legal OfficerSold plan15,000$18.32$274,800Form 4
May 21, 2026Karen FirestoneDirectorBought3,800$13.51$51,338Form 4
The latest 12 of 30 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 401,615.7%−269.1%—
Altman Z''8.85−9.697.18
Accruals ratio8.2%−37.7%−8.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassFailFail
Cash from operations is positivePassFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailPassFail
Gross margin rosePassFail—
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Amylyx Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Amylyx PharmaceuticalsFY25−100.0%—————
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Agios PharmaceuticalsFY2548.0%−873.9%−698.3%———Compare
AlkermesFY25−5.2%17.2%32.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

5 years of figures

Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue022381870
Revenue growth—7,700.0%1,612.9%−77.1%−100.0%
Gross profit—19355810
Research and development449412810490
Operating income−83−20139−315−153
Net income−88−19849−302−145
Diluted EPS (US$)−13.35−3.390.70−4.43−1.53
Diluted shares (millions)758706895
Cash flow
Cash from operations−75−18012−168−123
Capital expenditure02100
Free cash flow−75−18211−168−123
Dividends paid00000
Share buybacks00000
Acquisitions00000
Stock-based compensation322373328
Balance sheet at fiscal year end
Cash and short-term investments96347371176317
Debt incl. finance leases—————
Total assets106392518194333
Total liabilities1751842927
Shareholders' equity−151341433165305
Margins and ratios
Gross margin—86.5%93.3%93.2%—
Operating margin−29,013.3%−905.7%10.2%−360.2%—
Net margin−30,853.0%−892.4%12.9%−345.4%—
Free cash flow margin−26,369.1%−820.5%2.8%−192.1%—
Rule of 40 (growth + FCF margin)—6,879.5%1,615.7%−269.1%—
Return on capital—————
Return on equity—−209.4%12.7%−100.9%−61.6%
Return on assets—−79.8%10.8%−84.9%−55.0%
Net debt to EBITDA—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Amylyx Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Amylyx Pharmaceuticals.